newsfilter
← Latest News
PR Newswire·

Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China

Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV Key partnership with Vir enables multitude of combination treatment options as part of Company's strategic appro